Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human... see more

TSXV:CZO - Post Discussion

Ceapro Inc > Fairness opinions aren’t
View:
Post by lscfa on Feb 28, 2024 3:51pm

Fairness opinions aren’t

using volume weighted average stock prices for the 32 trading days before merger announcement gives CZO 63% of combined mkt cap but Bloom Burton says 50% is fair. It gives AEZS 37% of combined mkt cap but Raymond James says 50% is fair. What a crock.



 

$cdn

CZO

AEZS

Vwap nov1-dec 13

0.27

2.54

Shs o/s

78,293,177

4,855,876

Mkt cap 000’s

21,139

12,334

% Merged mc

63.2%

36.8%

Sept book equity

29,963

35,213

% merged b.e.

46.0%

54.0%

Comment by prophetoffactz on Feb 28, 2024 4:01pm
Gilles is in the best position to know the fairness of this deal given the partnering discussions around the diagnostic and PGX as well as his understanding of the pipelines.  H.C. Wainwright issued a US$15 price target for AEZS before much of the recent biotech surge. C$100-C$150 million market cap target could be fair for both companies making it a merger of equals.